Form 4: Cardlytics CEO Amit Gupta Sells Shares for Tax Obligations

Cardlytics CEO Amit Gupta exercised restricted stock units and subsequently sold a portion of the common stock to satisfy tax withholding obligations.

Summary

• Amit Gupta, Director and Chief Executive Officer of Cardlytics, Inc. (CDLX), reported transactions involving the company's common stock.
• On October 1, 2025, 14,350 shares of common stock were acquired upon the vesting of Restricted Stock Units (RSUs).
• On October 2, 2025, 7,799 shares of common stock were disposed of at a weighted average price of $2.271 per share.
• The sale was explicitly stated to be solely for satisfying tax withholding obligations resulting from the RSU vesting, with no other purpose for the sale.
• The shares were sold in multiple transactions at prices ranging from $2.21 to $2.36, inclusive.
• Following these transactions, Amit Gupta beneficially owns 498,310 shares of common stock directly.
• The original RSU award was for 114,796 shares, vesting in eight equal installments, with the reported vesting being one such installment.
• After the vesting and subsequent transactions, 28,699 derivative securities (RSUs) remain beneficially owned directly.

Sentiment

Score: 6

Explanation: The transaction is a routine insider sale to cover tax obligations upon RSU vesting, which is a common occurrence and not indicative of a negative outlook from the insider. The insider retains a substantial holding.

Positives

• The sale of shares was explicitly for tax withholding purposes, which is a routine event for executives receiving equity compensation and is generally viewed less negatively than a discretionary sale.
• The CEO retains a substantial beneficial ownership of 498,310 shares of common stock and 28,699 Restricted Stock Units, indicating continued alignment with shareholder interests.

Negatives

• The transaction involved a reduction in the CEO's direct common stock holdings by 7,799 shares, even if for tax purposes.
• The weighted average sale price of $2.271 per share is relatively low, which could reflect the company's stock performance at the time of vesting.

Future Outlook

The remaining installments of the RSU award are scheduled to vest on January 1, 2026, and April 1, 2026, contingent upon the Reporting Person's continued employment with the Issuer on those dates.

Management Comments

• "Shares were sold solely to satisfy tax withholding obligations that resulted from the delivery of shares of common stock for RSUs that vested on October 1, 2025. The Reporting Person did not sell shares for any other purpose."

Industry Context

N/A

Stakeholder Impact

• Shareholders: The transaction represents a routine insider activity for tax purposes, which is unlikely to have a significant direct impact on shareholder value. The CEO's continued substantial ownership aligns his interests with those of other shareholders.
• Employees: The vesting schedule for RSUs is tied to continued employment, which can serve as an incentive for executive retention.

Next Steps

• Future RSU installments are scheduled to vest on January 1, 2026, and April 1, 2026, subject to continued employment.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the CEO sold shares solely to cover tax obligations arising from RSU vesting. It does not indicate a change in the company's fundamentals or the CEO's long-term conviction. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

Cardlytics, CDLX, Amit Gupta, Insider Transaction, Form 4, RSU Vesting, Stock Sale, Tax Withholding, Equity Compensation, CEO